Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin

Thorax

Volumn 70, Issue 7, 2015, Pages 636-646

  Knippenberg, Sarah ^a   Ueberberg, Bianca ^a   Maus, Regina ^a   Bohling, Jennifer ^a   Ding, Nadine ^a   Tarres, Meritxell Tort ^a   Hoymann, Heinz Gerd ^b   Jonigk, Danny ^a   Izykowski, Nicole ^a   Paton, James C ^c   Ogunniyi, Abiodun D ^c   Lindig, Sandro ^d   Bauer, Michael ^d   Welte, Tobias ^a,e   Seeger, Werner ^e   Guenther, Andreas ^e   Sisson, Thomas H ^f   Gauldie, Jack ^g   Kolb, Martin ^g   Maus, Ulrich A ^a,e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^f UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMOXICILLIN; BACTERIAL TOXIN; CLARITHROMYCIN; DIPHTERIA TOXIN; DIPHTERIA TOXIN RECEPTOR; PNEUMOLYSIN; PROSTAGLANDIN E2; RECEPTOR; SURFACTANT PROTEIN C; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DIPHTHERIA TOXIN; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; PNEUMOCOCCUS VACCINE; STREPTOLYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FIBROGENESIS; GRAM POSITIVE INFECTION; KNOCKOUT MOUSE; LUNG ALVEOLUS EPITHELIUM CELL; LUNG FIBROSIS; MOUSE MODEL; NONHUMAN; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; STREPTOCOCCUS PNEUMONIAE; TRANSGENIC MOUSE; VACCINATION; WILD TYPE MOUSE; ANIMAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; IMMUNOLOGY; LUNG ALVEOLUS; LUNG LAVAGE; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; PNEUMONIA, PNEUMOCOCCAL; PULMONARY FIBROSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; DIPHTHERIA TOXIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PULMONARY ALVEOLI; PULMONARY FIBROSIS; STREPTOLYSINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84939239845     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206420     Document Type: Article

References (35)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-61.
3. McMillan TR, Moore BB, Weinberg JB, et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008; 177: 771-80.
4. Martinez FJ, Safrin S, Weycker D Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142(12 Pt 1): 963-7.
5. Collard HR, Moore BB, Flaherty KR Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-43.
6. Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 1698-702.
7. Kolb MR, Richeldi L. Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? Am J Respir Crit Care Med 2011; 183: 1583-4.
8. Molyneaux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev 2013; 22: 376-81.
9. Naik PK, Moore BB. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med 2010; 4: 759-71.
10. Ashley SL, Jegal Y, Moore TA, et al. gammaHerpesvirus-68, but not Psuedomonas aeruginosa or influenza A (H1N1) exacerbate established murine lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2014; 307: L219-30.
11. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014; 2: 548-56.
12. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190: 906-13.
13. Rodt T, von Falck C, Dettmer S, et al. Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfer of biologically active transforming growth factor-beta1. Respir Res 2010; 11: 181.
14. Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-76.
15. Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010; 181: 254-63.
16. Steinwede K, Henken S, Bohling J, et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 2012; 209: 1937-52.
17. Maus UA, Srivastava M, Paton JC, et al. Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space. J Immunol 2004; 173: 1307-12.
18. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-71.
19. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-51.
20. Kolodsick JE, Peters-Golden M, Larios J, et al. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003; 29: 537-44.
21. Maher TM, Evans IC, Bottoms SE, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182: 73-82.
22. Penke LR, Huang SK, White ES, et al. Prostaglandin E2 inhibits alpha-smooth muscle actin transcription during myofibroblast differentiation via distinct mechanisms of modulation of serum response factor and myocardin-related transcription factor-A. J Biol Chem 2014; 289: 17151-62.
23. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012; 15: 829-35.
24. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178: 139-48.
25. Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology 2012; 17: 802-7.
26. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 1117-24.
27. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013; 68: 155-62.
28. Canvin JR, Marvin AP, Sivakumaran M, et al. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 1995; 172: 119-23.
29. Kadioglu A, Gingles NA, Grattan K, et al. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 2000; 68: 492-501.
30. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-72.
31. Rubins JB, Duane PG, Clawson D, et al. Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun 1993; 61: 1352-8.
32. Bozyk PD, Moore BB. Prostaglandin E2 and the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 45: 445-52.
33. Cockeran R, Steel HC, Mitchell TJ, et al. Pneumolysin potentiates production of prostaglandin E(2) and leukotriene B(4) by human neutrophils. Infect Immun 2001; 69: 3494-6.
34. Harvey RM, Ogunniyi AD, Chen AY, et al. Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae in the blood. Infect Immun 2011; 79: 4122-30.
35. Berry AM, Ogunniyi AD, Miller DC, et al. Comparative virulence of Streptococcus pneumoniae strains with insertion-duplication, point, and deletion mutations in the pneumolysin gene. Infect Immun 1999; 67: 981-5.